ARS Pharmaceuticals, Inc. (SPRY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.62-0.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SPRY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on provider adoption and targeted engagement with high-volume prescribers to grow neffy market share and revenue.
Stated as a priority in 2 of last 2 quarters. neffy U.S. net product revenue grew from $17.5 million in 2026-Q1 to $26.2 million in 2026-Q2, with total U.S. epinephrine market share increasing to 5% in Q2 2026. Management's focus on targeted provider engagement aligns with this revenue growth, indicating delivering progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Announced shift to provider adoption with targeted engagement to grow market share and revenue.”
“Focused on expanding access and deepening prescriber adoption to drive market share growth.”
Reduce SG&A and R&D expenses through cost optimization to support profitable neffy franchise and path to cash flow breakeven by end of 2027.
Stated as a priority in 2 of last 2 quarters. SG&A expenses were $72.2 million in 2026-Q1 and $77.6 million in 2026-Q2, with management projecting a more than 40% reduction in SG&A cash expenses in the second half of 2026 and a path to cash flow breakeven by end of 2027. The trajectory shows management actively implementing cost discipline but operating expenses remain elevated in the latest quarter.
“Announced significant SG&A expense reduction and cost optimization framework.”
“SG&A expenses of $72.2 million reflecting consumer marketing and sales force expansion.”
Progress Phase 2b trial for chronic spontaneous urticaria (CSU) with interim data expected in Q1 2027 to expand intranasal epinephrine platform.
Stated as a priority in 2 of last 2 quarters. The Phase 2b trial for CSU is ongoing with interim data expected in Q1 2027. Management emphasizes this program as a potential major growth opportunity leveraging existing infrastructure. The clinical development is progressing on schedule, indicating delivering progress.
“Interim data from Phase 2b CSU trial expected in Q1 2027; no FDA-approved on-demand treatment exists.”
“Phase 2b CSU study interim population fully enrolled, on track for Q4 2026 readout.”
Complete sales force expansion and appoint new Chief Commercial Officer to drive focused provider engagement and market share growth.
Newly stated in 2026-Q2. Management completed the sales force expansion and appointed a new Chief Commercial Officer to lead targeted provider engagement. The sales force reached 148 representatives by 2026-Q1. This priority is recently emphasized with initial delivery on leadership and sales force expansion.
“Completed sales force expansion and appointed Meg Smith as Chief Commercial Officer.”
Continue to grow revenue through strong execution and expanding prescribing experience.
Over the trailing year it converted 0.98x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.